# Wellpartner

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wellpartner

- Industry: Business Support Services
- Headquarters: New York, US
- Website: www.wellpartner.com
- Total disclosed funding: $34M
- Latest round: Series E (Feb 13, 2012)
- Investors on record: 8

## About

Wellpartner, Inc. is a healthcare technology company that specializes in providing comprehensive support services for the 340B drug pricing program, enhancing compliance and program management for its clients.Founded in 2000 and headquartered in New York, US, Wellpartner, Inc. operates in the healthcare sector, delivering services tailored to the 340B program. The company has executed 11 deals, with the latest being a Series E funding round on February 13, 2012, where it raised USD 3.000 mn from Integra Ventures. The current valuation of the company is USD 68.720 mn.Wellpartner specializes in comprehensive support services tailored to the unique demands of the 340B drug pricing program. Their primary offerings include a suite of technology solutions designed to enhance program management and compliance, coupled with expert consulting services. Wellpartner’s solutions are crafted to help healthcare providers navigate the complexities of the 340B landscape, ensuring they can maximize their savings while maintaining compliance with regulatory requirements. The company serves a diverse client base, including hospitals, health systems, and community health organizations across the United States, facilitating access to essential medications for underserved populations.Wellpartner generates revenue through a structured model that integrates subscription-based services and consulting engagements specifically designed for 340B program management. Clients typically engage in partnerships that involve ongoing support and technology integration, allowing for a seamless alignment of services with organizational needs. The company’s flagship solutions include 340B Clarity and 340B Compliance, which offer tailored insights and regulatory assistance to maximize program efficiency. Revenue is derived from these service contracts, where healthcare organizations pay for access to Wellpartner’s technology and expertise on a recurring basis.Wellpartner plans to leverage its recent Series E funding, raised in February 2012, to support the development of new products aimed at enhancing its technology offerings for the 340B program. The company is also exploring opportunities to expand its services into additional states within the US, with a focus on enhancing accessibility for healthcare providers in underserved regions. By implementing these strategies, Wellpartner aims to strengthen its position in the healthcare technology sector while continuing to support compliance and efficiency within the 340B program.

## Funding rounds

- Series E, Feb 13, 2012, $3M — Integra Ventures
- Series D, Jul 29, 2008, $16M — 3i, Burrill & Company, Integra Ventures, Mediphase Venture Partners, Montlake Capital, Scorpion Capital Partners, Credit Suisse, Greenwoods Capital Partners
- Series C, Feb 21, 2007, $7.5M — 3i, Integra Ventures, Mediphase Venture Partners, Montlake Capital, Scorpion Capital Partners, Greenwoods Capital Partners
- Series B, Dec 7, 2005, $2M — Scorpion Capital Partners
- Series A, Jan 12, 2005, $5M — Scorpion Capital Partners

## Investors

- Scorpion Capital Partners (https://capitalatlas.ai/funds/scorpion-capital-partners) — Series A, Series B, Series C, Series D
- 3i (https://capitalatlas.ai/funds/3i) — Series C, Series D
- Integra Ventures (https://capitalatlas.ai/funds/integra-ventures) — Series C, Series D, Series E
- Mediphase Venture Partners (https://capitalatlas.ai/funds/mediphase-venture-partners) — Series C, Series D
- Montlake Capital (https://capitalatlas.ai/funds/montlake-capital) — Series C, Series D
- Greenwoods Capital Partners (https://capitalatlas.ai/funds/greenwoods-capital-partners) — Series C, Series D
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series D
- Credit Suisse (https://capitalatlas.ai/funds/credit-suisse) — Series D